The efficacy of Ropinirole in the improvement of ADHD

Phase 2

• Conditions: ADHD.; Attention-deficit hyperactivity disorder, combined type; F90.2

• Registration Number: IRCT20090117001556N151
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 June 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

ADHD diagnosis based on DSM5
Children between 6-17 years old.

Exclusion Criteria

Presence of severe medical illness, neurological problems and problems requiring surgery
Presence of any concomitant psychiatric disorder that requires treatment with psychiatric drugs except ODD
History of treatment with ropinirole in the three months prior to the study
Consumption neuroleptic medication in the last 6 months
Weight less than 13.5 kg
Mental retardation
Uncontrolled seizure disorder
Systolic blood pressure above 125 mm Hg or Resting pulse rate less than 60 beats per minute or above 115 beats per minute
Using any medicine or supplement for the treatment of ADHD
History of allergy to methylphenidate or ropinirole

Study & Design

• Study Type: interventional
• Study Design: Not specified